Results 201 to 210 of about 15,820 (232)

Endothelin, endothelin receptors, and endothelin antagonists.

Current opinion in nephrology and hypertension, 1995
Endothelin is a peptide with potent biologic effects in vascular and nonvascular cells. Its effects are mediated by two receptors, ETA and ETB, and possibly also by a third receptor, ETC. In vascular smooth muscle cells, endothelin causes profound contraction and also has proliferative effects, mainly through activation of ETA but also through ETB ...
openaire   +1 more source

Bosentan: a dual endothelin receptor antagonist

Expert Opinion on Investigational Drugs, 2002
The peptide endothelin plays a significant role in a wide array of pathological conditions, including primary pulmonary hypertension and pulmonary arterial hypertension associated with collagen vascular disease. These are life-threatening conditions that can severely compromise the function of the lungs and heart.
Lewis J, Rubin, Sébastien, Roux
openaire   +2 more sources

Endothelin Receptor Antagonist

2017
Endothelin (ET)-1, a peptide mainly produced by vascular endothelial cells, has potent and long-lasting vasoconstrictive effect. In addition, ET-1 has been shown to induce a variety of biological effects including cell proliferation, inflammation, and fibrosis.
openaire   +1 more source

Update on Endothelin Receptor Antagonists in Hypertension

Current Hypertension Reports, 2018
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the treatment of hypertension and the management of diabetic nephropathy RECENT FINDINGS: Recent reviews and meta-analyses of experimental and clinical data obtained with ERAs confirmed that endothelin receptor blockade is associated with significant ...
openaire   +3 more sources

Endothelin receptor antagonists: a brief review

Canadian Journal of Physiology and Pharmacology, 1994
The endothelins are a family of potent vasoconstrictors, some of which also have vasodilatory activity. In many diseases associated with tissue hypoxia or ischemia and in diseases in which vasoconstriction plays a role, the circulating levels of endothelin are higher than in healthy, control subjects.
openaire   +2 more sources

Endothelin receptor antagonists: Actions and rationale for their development

Biochemical Pharmacology, 1994
Timothy D Warner, Bruno Battistini, Annette M Doherty   +2 more
exaly  

[Endothelin receptor antagonist].

Nihon rinsho. Japanese journal of clinical medicine, 2000
S, Sakai, T, Miyauchi, Y, Sugishita
openaire   +3 more sources

Endothelin receptor antagonists for the treatment of pulmonary artery hypertension

Life Sciences, 2012
Lewis J Rubin
exaly  

Endothelin receptor antagonists‐induced hepatotoxicity

Internal Medicine Journal, 2013
D, Macías Saint-Gerons, C, de la Fuente Honrubia, D, Montero, F, Catalá-López   +3 more
openaire   +2 more sources

The role of endothelin-1 and endothelin receptor antagonists in prostate cancer

BJU International, 2000
M A Carducci, J B Nelson
exaly